Objective-We previously reported that cardiac-restricted deletion of focal adhesion kinase (FAK) exacerbated myocyte death following ischemia/reperfusion (I/R). Here, we interrogated whether targeted elevation of myocardial FAK activity could protect the heart from I/R injury. Methods and Results-Transgenic mice were generated with myocyte-specific expression of a FAK variant (termed SuperFAK) that conferred elevated allosteric activation. FAK activity in unstressed transgenic hearts was modestly elevated, but this had no discernable effect on anabolic heart growth or cardiac function. Importantly, SuperFAK hearts exhibited a dramatic increase in FAK activity and a reduction in myocyte apoptosis and infarct size 24 to 72 hours following I/R. Moreover, serial echocardiography revealed that the transgenic mice were protected from cardiac decompensation for up to 8 weeks following surgery. Mechanistic studies revealed that elevated FAK activity protected cardiomyocytes from I/R-induced apoptosis by enhancing nuclear factor-B (NF-B)-dependent survival signaling during the early period of reperfusion (30 and 60 minutes). Moreover, adenoviral-mediated expression of SuperFAK in cultured cardiomyocytes attenuated H 2 O 2 or hypoxia/reoxygenation-induced apoptosis, whereas blockade of the NF-B pathway using a pharmacological inhibitor or small interfering RNAs completely abolished the beneficial effect of SuperFAK. Conclusion-Enhancing cardiac FAK activity attenuates I/R-induced myocyte apoptosis through activation of the prosurvival NF-B pathway and may represent a novel therapeutic strategy for ischemic heart diseases. (Arterioscler Thromb Vasc Biol. 2012;32:924-933.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C ardiovascular diseases are the number 1 cause of death globally, and current estimates indicate that as many as 1 of 6 deaths per year in the United States can be attributed to coronary disease and associated myocardial ischemia. 1 Although rapid reperfusion is necessary to reduce ischemiadependent myocyte necrosis, it can also result in intracellular calcium overload and oxidative stress, which can initiate apoptosis. 2 Importantly, although apoptosis can account for up to 60% of myocyte death within infarcted tissue, 3 this programmed cell death cascade (unlike necrosis) can be reversed by activation of prosurvival signals. 4, 5 Therefore, defining the mechanisms that govern the transition between cardiomyocyte apoptosis and survival will undoubtedly have a significant impact on the generation of promising treatments to reduce ischemia-induced myocardial dysfunction.
Attachment of cells to the extracellular matrix results in the clustering of integrin receptors and initiates the recruitment of numerous structural and catalytically active signaling proteins to the adhesion complexes that are necessary for maintaining tissue integrity, for conveying tensile strength, and for the transduction of growth and survival signals. 6 Several recent studies indicate that integrin signaling may play a pivotal role in preserving the myocardium from pathological stressors. For example, myocardial-restricted deletion of ␤ 1 integrin in mice leads to myocardial dysfunction in postpartum females and in male mice subjected to hemodynamic overload. 7, 8 As well, mice with myocyterestricted depletion of ␤ 3 integrin exhibit elevated cardiomyocyte apoptosis and concomitant heart failure following isoproterenol infusion. 9 Moreover, the finding that human ischemic cardiomyopathy is associated with downregulation of the muscle selective ␤ 1 D-integrin and the integrinactivated kinase focal adhesion kinase (FAK) supports the possibility that targeting this pathway may be beneficial in the prevention of ischemic human heart failure. 10 Nearly two thirds of the known integrin heterodimers, including all ␤ 1 -, ␤ 3 -, or ␤ 5 -containing integrins, couple to the nonreceptor protein tyrosine kinase FAK, 11, 12 as do several growth factor receptors, including those activated by vascular endothelial growth factors and fibroblast growth factors. 13, 14 FAK activation proceeds by a 2-step process that involves dimerization and autophosphorylation of Tyr397, which creates a high-affinity Src homology 2 binding site for the tyrosine kinase Src. Once bound, Src phosphorylates FAK on 2 additional sites within the activation loop (Tyr576 and Tyr577), leading to further enhancement of FAK catalytic activity. FAK binding partners/substrates include the adapter proteins paxillin, p130 CAS, and GRB2, [15] [16] [17] [18] which can activate the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase growth promoting mitogen-activated protein kinases. FAK also coordinates signaling to the prosurvival nuclear factor-B (NF-B) 19, 20 and Akt 19 pathways through interactions with receptor-interacting protein and Pi3 kinase, respectively. Although FAK activity is necessary for myocyte proliferation and midgestational heart growth, we recently showed that myocyte-specific deletion of FAK in the adult myocardium did not affect anabolic growth or basal contractility. 21 However, on challenge, FAK-depleted hearts progressed to profound cardiac decompensation following pressure overload 21 and exhibited markedly increased myocyte apoptosis and infarct size relative to wild-type mice following ischemia/reperfusion (I/R). 22 Because our mechanistic studies supported a critical role for myocardial FAK in promoting NF-B-induced survival signaling following I/R, we predicted that enhanced myocardial FAK activity might provide cardioprotection from an ischemic insult.
To date, attempts to enhance prosurvival signaling in the myocardium by expression of upstream kinases have met with limited success, likely because of strategies that often lead to supraphysiological expression of constitutively active kinases. In these cases, overexpression alone can lead to striking changes in myocardial remodeling that culminate in phenotypes ranging from hypertrophy to heart failure and sudden death as has been observed in several transgenic mouse models with targeted expression of active Akt variants. [23] [24] [25] [26] [27] Because we hypothesized that transient elevation of FAK-dependent survival signals would be cardioprotective, whereas uncontrolled activation could lead to detrimental remodeling, we sought to express a variant of FAK that requires signal-dependent activation but exhibits enhanced catalytic activity. Thus we took advantage of known mutations within the FAK activation loop (Lys578Glu/ Lys581Glu) that mimic the charge transfer (and enhanced catalytic activity) induced by Src phosphorylation. 28 Herein, we found that transgenic mice with myocyte-restricted expression of this superactivatable FAK variant (termed SuperFAK [SF]) exhibited remarkable protection from I/R-dependent cell death. These studies provide the first evidence that FAK could be a tractable target for gene therapy and provide proof-of-concept for a methodological approach to exploit posttranslational modifications to enable spatial and temporal control of kinase activation in vivo.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Generation of SF Transgenic Mice
The SF cDNA variant was kindly provided by Dr Michael Schaller. 28 Cardiac-specific transgenic mice with SF overexpression was achieved with a 3.4-kb piece of the cardiac ␤-myosin heavy chain promoter that was modified to prevent downregulation at birth. 29 All animals were housed in a university animal care facility accredited by the American Association for Accreditation of Laboratory Animal Care, and all procedures were approved by the University of North Carolina Institutional Animal Care and Use Committee.
Statistical Analysis
All values are presented as meansϮSEM. Comparisons were performed by using unpaired Student t test or 1-way analysis of variance with the Tukey's post hoc test as appropriate. All tests were 2-tailed, and significance was accepted at PϽ0.05.
Results

Generation of Transgenic Mice That Confer Enhanced Allosteric FAK Activity in the Myocardium
We previously demonstrated that cardiac-restricted deletion of FAK exacerbates I/R-induced apoptosis and leads to enhanced cardiac decompensation following I/R or prolonged pressure overload. 21, 22 Because the toggling between prosurvival and proapoptotic signals remains central to preventing irreversible damage to the heart, 30 we strove to determine whether enhanced FAK activity could salvage at-risk myocytes in the ischemic heart. To address this critical issue, we generated transgenic mice that expressed a superactivatable variant of FAK (SF) in cardiomyocytes. SF contains glutamic acid substitutions for 2 lysine residues in the activation loop of FAK (Lys578Glu, Lys581Glu) that render the protein primed for allosteric activation ( Figure IA in the online-only Data Supplement). 28, 31 SF has substantially increased catalytic activity in comparison to wildtype FAK when expressed at comparable levels ( Figure IB in the online-only Data Supplement). Nonetheless, SF is not constitutively active. Indeed, cells transfected with SF for 48 hours and maintained on tissue culture plastic exhibited levels of FAK activity comparable to those of nontransfected or LacZtransfected cells ( Figure 1A , left). However, when replated on a fibronectin-coated surface for 30 minutes, the SF transfected cells exhibited much more pronounced FAK activity ( Figure 1A , right), indicating that SF confers enhanced allosteric activation.
Two novel mouse lines were generated in which a flagepitope tagged SF transgene was expressed under the control of a truncated ␤-myosin heavy chain promoter that was modified to drive cardiomyocyte-specific expression into adulthood. 29 The so-named SF1 and SF2 mice exhibited a persistent and myocardial-restricted increase (2-to 6-fold respectively) in basal cardiac FAK activity relative to agematched nontransgenic (NTG) littermate control hearts (Figure 1B-1D ). Both SF1 and SF2 mice were born in the expected Mendelian frequency, and no noticeable morbidity or mortality was observed up to 18 months of age.
Enhanced Cardiomyocyte-Specific FAK Activity Does Not Influence Cardiac Growth or Basal Cardiac Function
We carefully assessed the consequence of elevated myocyterestricted FAK activity on postnatal myocardial growth in SF1 and SF2 mice. No significant differences were observed in myocardial shape or size ( Figure IIA To determine whether elevated myocyte-specific FAK activity affected cardiac performance, we first measured left ventricular function by conscious echocardiography in young adult male SF2 and NTG control mice. No significant differences in either ejection fraction or fractional shortening were observed between these lines ( Figure IIE and IIF in the online-only Data Supplement). As well, serial echocardiography in a second cohort of anesthetized mice revealed comparable left ventricular wall thickness, chamber diameter, mass, and function between NTG and SF2 mice from 1 to 12 months of age ( Figure IV in the online-only Data Supplement). Hemodynamic measurements by cardiac catheterization also revealed no significant differences in intrinsic cardiac contractility or diastolic function between 12-monthold NTG and SF2 mice ( Figure V in the online-only Data Supplement). Taken together with our previous findings, 21, 32 these data indicate that FAK activity is neither necessary nor sufficient to promote anabolic cardiac growth. Moreover, although we and others previously found that FAK was necessary for the promotion of pathological cardiac remodeling following pressure overload, 21, 33 we found no signs of pathological hypertrophy in either SF line. Quantitative reverse transcription-polymerase chain reaction for the canonical hypertrophy marker atrial natriuretic factor revealed no significant difference between SF2 and NTG ( Figure IIG in the online-only Data Supplement). Levels of myocardial fibrosis as assessed by Masson's Trichrome staining was also comparable between control and SF2 mice for up to 1 year of age, consistent with our findings that systolic function was maintained in these mice ( Figure 
Elevated FAK Activity Ameliorates Adverse Cardiac Remodeling and Dysfunction Following I/R
Because we previously showed that cardiac-restricted deletion of FAK exacerbated I/R-induced myocardial infarction, 22 we hypothesized that elevated FAK activity would confer cardioprotection in this setting. To this end, we subjected NTG and SF2 mice to 30 minutes of ischemia (induced by transient ligation of the left anterior descending coronary artery) followed by reperfusion for 24 hours to 8 weeks and assessed infarct size and myocardial function. Evans blue/2,3,5-triphenyltetrazolium chloride staining showed that the relative area at risk (nonblue/ total left ventricular area) was comparable between the 2 groups, indicating that a similar level of ischemia was induced following surgical ligation (data not shown). However, 24 hours following reperfusion, the SF2 mice exhibited a significantly decreased relative infarct size (white/nonblue area) compared with control mice (control, 50.5Ϯ6.0%, vs SF2, 34.6Ϯ3.2%; PϽ0.05; nϭ6 for control and nϭ7 for SF2; Figure 2A , top, and 2B). A much greater difference was observed between the 2 groups after 72 hours of reperfusion (control, 79.4Ϯ4.1%, vs SF2, 34.7Ϯ5.6%; PϽ0.001; nϭ5 for control and nϭ4 for SF2; Figure 2A , bottom, and 2B). Notably, in the NTG controls the relative infarct size increased dramatically from 24 to 72 hours following I/R, whereas the SF2 mice exhibited no significant increase in infarct size during this critical time period. To determine whether SF expression promoted longterm cardioprotection, cardiac function was monitored by conscious echocardiography at 2, 4, and 8 weeks post-I/R in a third cohort of NTG and SF2 mice. Both interventricular septal and posterior wall thickness were much better preserved in the SF2 hearts ( Figure VII in the online-only Data Supplement). Concomitantly, although both groups exhibited a decline in ejection fraction and fractional shortening following I/R, the SF2 hearts maintained significantly greater function than the NTG controls ( Figure 2C and 2D ). Ultimately, I/R-induced chamber dilatation was observed in the NTG but not SF2 hearts at the 4-and 8-week time points ( Figure VII in the online-only Data Supplement). Collectively, these data indicate that enhanced myocardial FAK activity protects the myocardium from I/R-dependent cell death and promotes functional recovery following an ischemic insult.
Elevated FAK Activation Attenuates Cardiomyocyte Apoptosis Following I/R
I/R-induced myocyte death results from irreversible (necrotic) and reversible (apoptotic) signals. Because our previous studies indicated that FAK depletion renders cardiomyocytes more susceptible to ischemia-induced apoptosis, we reasoned that enhanced FAK activity might limit cardiomyocyte apoptosis following I/R. We first sought to determine the extent to which SF is activated in ischemic myocytes. To aid in the demarcation of the ischemic zone, I/R-treated mice were injected with hypoxyprobe-1 (pimonidazole hydrochloride), which forms protein adducts in cells with a pO 2 of 10 mmHg or less that can be detected by immunostaining. 34 As shown in Figure 3A , sham SF2 hearts contained little immunoreactivity for hypoxyprobe-1, whereas those subjected to I/R for 24 hours revealed intense focal reactivity, typical of hypoxia. Consistent with previous studies from us and others indicating that wild-type FAK was activated following I/R 22 or ischemic preconditioning, 35 costaining with the phospho-FAK(Tyr397) antibody revealed that FAK activity was relatively low in sham SF2 hearts but was markedly induced within the hypoxic myocytes in I/R treated SF2 hearts ( Figure  3A ). As expected, the magnitude of ischemia-induced FAK activation was much higher in SF2 hearts than control hearts subjected to I/R despite a similar extent of hypoxyprobe staining ( Figure 3B and data not shown), indicating that SF is primed for robust activation in response to myocyte hypoxia. We next asked whether ischemic myocytes with elevated FAK activity were more resistant to I/R-induced apoptosis. As shown in Figure 3B and 3C, the number of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive myocytes 24 hours following I/R was significantly lower in the SF2 hearts than in NTG controls in both the ischemic border zone and in remote regions. Moreover, SF2 hearts exhibited a stark reduction in I/R induced cleaved caspase 3 levels as assessed by immunohistochemistry ( Figure VIII in the online-only Data Supplement). Taken together with our results that infarcts in SF2 hearts did not increase between 24 and 72 hours following I/R (time points at which apoptosis contributes significantly to myocyte death), these studies provide strong evidence that enhanced FAK activity can protect myocytes from ischemia-induced apoptosis. Importantly, capillary and coronary vascular density was comparable between control and SF2 hearts ( Figure IX in the online-only Data Supplement), indicating that the beneficial effect of elevated FAK activity was likely myocyte autonomous and was not due to enhanced collateral blood flow.
Elevated FAK Activity Protects Cultured Cardiomyocytes From Oxidative Stress-Induced Apoptosis
We developed an in vitro assay to further test whether elevated FAK activity confers protection from ischemia- induced programmed cell death in a cell-autonomous fashion. To this end, we infected primary neonatal rat cardiomyocytes with adenoviruses expressing green fluorescent protein (GFP) or SF and subjected these cells to oxidative stress by treatment with 10 mol/L H 2 O 2 or by incubation in low O 2 as previously described. 22 Oxidative stress is known to play a critical role in I/R-induced cardiomyocyte apoptosis, 2 and we found that treatment of cultured cardiomyocytes with 10 mol/L H 2 O 2 for 5 hours induced marked apoptosis in noninfected or GFP-infected cardiomyocytes (as assessed by TUNEL), whereas significantly fewer TUNEL-positive cells were found in SFinfected cultures ( Figure 4A ; Figure X in the online-only Data Supplement). SF also decreased TUNEL in neonatal rat cardiomyocytes subjected to hypoxia (1% O 2 ) for 2 hours followed by reoxygenation for 1 hour, which closely mimics the hypoxia observed following I/R in vivo ( Figure 4B ). 22 As a secondary measure of apoptosis, we evaluated cleavage of caspase 3 in cell lysates by Western analysis. As shown in Figure X in the online-only Data Supplement, H 2 O 2 treatment led to cleavage of caspase 3 in GFP-infected but not SF-infected neonatal rat cardiomyocytes. Taken together, these data indicate that FAK acts in a cell-autonomous fashion to protect myocytes from oxidative stress-induced apoptosis.
SF Enhanced Nuclear Translocation and Transcriptional Activity of NF-B in Cardiac Myocytes
Because we recently showed that FAK was required for I/Rmediated activation of NF-B, and some studies indicate that NF-B protects cardiomyocytes from I/R-induced apoptosis, 22, [36] [37] [38] we interrogated the activity of this pathway in NTG and SF2 hearts. As shown in Figure 5 , SF2 hearts subjected to 30 minutes of ischemia followed by 30 or 60 minutes of reperfusion exhibited increased levels of phosphorylated Ser32/36 IB␣ relative to control hearts, with a concomitant decrease in IB␣ levels, and enhanced phosphorylation of p65 (Ser536) that returned to baseline by 24 hours of reperfusion ( Figure 5A 
FAK-Dependent Resistance to Oxidative Stress Requires NF-B Signaling
To confirm that regulation of NF-B was attributable to a primary change in myocyte FAK activity, we next examined activation of this survival pathway in cultured cardiomyo-cytes. As expected, SF expressing cardiomyocytes that were plated on FN to induce FAK activity exhibited a decrease in IB␣ and a concomitant increase in NF-B activity ( Figure  XIII in the online-only Data Supplement) and expression of 2,3,5-triphenyltetrazolium chloride, bcl-2 and bcl-xl ( Figure  6A ) compared with noninfected or GFP-infected cells. To determine the functional importance of this survival pathway with respect to SF-dependent protection from oxidative stress, we next explored whether inhibition of NF-B signaling would restore myocyte apoptosis in SF-expressing cardiomyocytes. As shown in Figure 6A , treatment with JSH-23, a cell-permeable inhibitor of NF-B p65 nuclear translocation, suppressed the capacity of SF to induce 2,3,5triphenyltetrazolium chloride, bcl-2 and bcl-xl expression. Moreover, although treatment of JSH-23 had little effect on H 2 O 2 -or hypoxia/reoxygenation-induced apoptosis in GFPexpressing cells, it completely abolished the protection conferred by SF overexpression (Figure 6B and 6C) . Indeed, in the vehicle control group, the number of TUNEL-positive SF expressing cardiomyocytes was significantly lower than GFP-expressing cardiomyocytes exposed to oxidative stress, whereas the numbers of TUNEL-positive SF-and GFPexpressing cardiomyocytes were comparable in cultures pretreated with JSH-23. We next used small interfering RNAs targeted toward the p65 NF-B transcript to confirm a role for this pathway in SF-mediated myocyte survival. As shown in Figure 6D to 6F, treatment of cultured cardiomyocytes with NF-B small interfering RNAs led to an approximate 90% reduction of p65 levels as assessed by Western blotting and nearly completely reversed the beneficial effect of SF expression when cells were exposed to H 2 O 2 or hypoxia/reoxygenation. In combination, these results indicate that induction of the NF-B pathway is a major mechanism by which elevated FAK activity confers cardioprotection.
Discussion
Ischemic heart disease is a significant cause of morbidity and mortality worldwide, and thus an enormous interest exists for the development of cardioprotective gene therapies. One potentially promising avenue involves attempts to enhance the activity of intrinsic prosurvival signals that are hard-wired in postmitotic cardiomyocytes to impart relatively high levels of resistance to oxidative stress. Under physiological conditions, most signaling molecules exhibit transient waves of activation to achieve the appropriate biological response, and 1 of the current challenges of this therapeutic approach is how to achieve such spatial and temporal control of prosurvival signals, because prolonged activation can lead to maladaptive cardiac remodeling. [25] [26] [27] We previously reported that FAK plays an important role in the induction of intrinsic survival pathways in cardiomyocytes following I/R and sought to explore whether targeted FAK activation might ameliorate ischemia-induced apoptosis. To this end, we used the knowledge that mutations in the activation loop of FAK enhanced catalytic activity but also required signal-dependent activation for maximal induction. We found that transgenic mice that expressed this superactivatable variant of FAK (SF) in the myocardium exhibited elevated FAK activity in unstressed hearts without consequence on cardiac growth or function. Importantly, FAK activity was profoundly increased in SF expressing hearts following I/R, and these hearts displayed remarkable cardioprotection. Indeed, hearts with transiently elevated FAK activity exhibited a dramatic reduction in myocyte apoptosis and infarct size and were protected from myocardial infarction-induced cardiac decompensation. We reason that the attenuation of myocyte apoptosis and initial infarct size by FAK activation leads to a long-standing benefit in contractile performance.
It is important to note that our studies reflect a beneficial effect of FAK when activated solely in cardiomyocytes. Interestingly, a recent study revealed that germline deletion of the extracellular matrix component fibronectin-extra domain A, a major fibronectin splice variant, did not affect infarct size but prevented adverse ventricular remodeling following myocardial infarction, an effect attributed to reduced activation of leukocytes and cardiac fibroblasts that resulted in lower levels of inflammation and metalloproteinase 2 and 9 activities. 40 Although FAK activity was not directly evaluated in these hearts, a separate study revealed that treatment of fibroblasts with fibronectin-extra domain A induced myofibroblast differentiation by a mechanism that involved binding to the ␣ 4 ␤ 7 integrin and inducing integrin-dependent activation of FAK. 41 These studies corroborated earlier findings that FAK can induce inflammatory cytokine production in fibroblasts. 42 Although myofibroblasts (ie, activated cardiac fibroblasts) are important for the initial healing responses following myocardial infarction, these cells also contribute to pathological fibrosis and detrimen- tal cardiac remodeling. Thus, one might expect that widespread activation of FAK throughout the myocardium would not likely provide as beneficial an effect as was observed herein following specific cardiomyocyte activation, and caution should be taken when devising therapeutic strategies to activate this molecule for cardioprotective purposes.
Our mechanistic studies revealed that elevated FAK activity protected cardiomyocytes from oxidative-stress induced apoptosis, at least in part, through enhanced intrinsic NF-Bdependent survival signaling. These findings confirm and extend our previous loss-of-function studies indicating that FAK was necessary for NF-B activation in cardiomyocytes exposed to oxidative stress and studies from others indicating that FAK is required for NF-B activation and survival of fibroblasts exposed to cytokines 20 and endothelial cells exposed to shear stress. 43 FAK has been shown to induce NF-B activation by forming a complex with the tumor necrosis factor receptor-associated factor 2 and receptorinteracting protein and facilitating the phosphorylation/activation of the upstream kinase IB kinase. 44 Because we observed increased phosphorylation of the IB kinase substrate, IB␣ in the SF2 hearts relative to controls, it is likely that a similar mechanism resulted in FAK-dependent activation of NF-B signaling in these hearts. Petzold et al reported that FAK may facilitate NF-B activation by different mechanisms in cytokine versus shear stress-induced stress signaling. 43 These authors found that following mechanical signals, FAK acts in a direct fashion to promote NF-B phosphorylation and activation. 43 Although we did find elevated activity of the IB kinase and decreased levels of IB in the SF2 hearts, our data do not rule out the possibility that I/R-dependent activation of FAK also directly augments NF-B activity.
Cardiomyocytes are known to be particularly sensitive to the levels of NF-B-dependent survival genes. Indeed studies in cultured myocytes indicated that NF-B suppressed mitochondrial defects and apoptosis through transcriptional upregulation of survival genes (including bcl-2, bcl-xl, and X-linked inhibitor of apoptosis protein) or by silencing proapoptotic genes, such as bnip3. 36, 45, 46 However, the function of NF-B in the intact heart is controversial, as it has been reported to induce both prosurvival and proapoptotic signals. 37, 38, 47, 48 More recent studies indicate that timing of activation may be causal for this disparity. 36, 47, 48 Thus, although acute myocyte NF-B activation promotes cardioprotection, chronic myocyte NF-B activation leads to an exacerbated inflammatory response and resulted in maladaptive remodeling. 36 Our studies are consistent with a FAK-dependent cardioprotective effect of transient NF-B activation, as we found elevated NF-B activity in the SF2 hearts 30 to 60 minutes following I/R and a return to baseline by the 24-hour time point. To determine which cell type was responsible for elevated NF-B activity in SF2 hearts, immunohistochemistry was performed with an NF-B p65-specific antibody. Our results showed that enhanced nuclear translocation of NF-B p65 was present in cardiac myocytes of SF2 hearts compared with NTG hearts (Figure 5D ), although we cannot exclude the possibility that NF-B is activated in additional resident heart cells, such as the endothelium, in which I/R has been reported to lead to activation of NF-B. 49 Moreover, although we did not observe enhanced activation of other major survival signals, such as ERK1/2 or Akt, in the SF2 hearts, it is formally possible that other FAK-dependent survival pathways contribute to the cardioprotective effects of FAK. Nonetheless, our finding that blockade of NF-Bdependent signals reverses the protection induced by SF expression in cardiomyocytes exposed to oxidative stress indicates that intrinsic NF-B activation does play a causative role in FAK-mediated myocyte survival.
We and others have previously identified a significant role for FAK in mediating the robust growth responses necessary for both midgestational cardiac development and the promotion of pressure-overload induced myocyte hypertrophy 21, 33, 50 but not for anabolic cardiac growth. Subsequent mechanistic studies indicated that basal FAK activity in embryonic hearts was necessary to repress p38 kinase activity and to promote cardiomyocyte cell cycle progression through G 2 /M. 32 However, in terminally differentiated cardiomyocytes, we found that FAK activity was necessary for ERK-dependent promotion of pathological hypertrophic growth. 32 Although postnatal SF2 hearts exhibited elevated levels of FAK activity, no change in cardiac ERK activity was observed, consistent with previous findings that SF did not enhance adhesion-or serum-stimulated ERK activation in cultured cells. 28 Concomitantly, adult SF2 hearts exhibited no signs of pathological hypertrophic remodeling. Indeed, SF2 and littermate control NTG mice had comparable heart weight/body weight ratios, cardiomyocyte cross-sectional area, atrial natriuretic factor expression, and cardiac function. These results confirm and extend previous studies indicating that overexpression of wild-type FAK in neonatal rat cardiomyocytes did not increase stretch-induced atrial natriuretic factor expression. 51 Taken together, these data indicate that FAK is necessary but not sufficient to promote ERK activation and pathological hypertrophic growth.
In sum, there are 2 major findings from the studies presented herein: (1) they support the feasibility of exploiting mutations in the activation domain of kinases to augment the successes of gene therapy approaches, and (2) they indicate that methodologies to enhance FAK activity (including administration of upstream agonists, 52, 53 or possibly via ischemic pre-and postconditioning 35, 53 or heat shock 35 ) may represent a novel therapeutic strategy for ischemic heart diseases. Because several recently developed chemotherapeutic agents that target receptor tyrosine kinases upstream of FAK, including sunitinib and imatinib, induce myocyte apoptosis and cardiomyopathy, 54, 55 it will be of future importance to evaluate whether enhancing FAK activation might also be an effective strategy to preserve myocardial function in this setting.
